COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
31/01/2025
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025. Accordingly, any shares of the [...]
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
31/01/2025
● Q4 and FY Test volume increase 21% and 17% year-over-year ● Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“ [...]
ARCPOINT ANNOUNCES C$800,000 NON-BROKERED PRIVATE PLACEMENT
31/01/2025
For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint [...]
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
31/01/2025
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the [...]
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
31/01/2025
Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 [...]
NewGen Announces Reverse Stock Split
31/01/2025
NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025 BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive [...]
Retrieve Medical Expands into Ambulatory Care with New Client Engagement
31/01/2025
BEDMINSTER, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Retrieve Medical, Inc. ( www.retrievemedical.com ) announces its expansion into the ambulatory care sector through a new client engagement with Saint Joseph’s Medical [...]
Immutep Quarterly Activities Report Q2 FY25
31/01/2025
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT- [...]
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
31/01/2025
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
31/01/2025
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare [...]
SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market
31/01/2025
DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for [...]
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
31/01/2025
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch [...]
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
31/01/2025
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Quipt Home Medical Responds to Kanen Wealth Management
31/01/2025
Reaffirms commitment to enhancing shareholder value and strong corporate governance CINCINNATI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home [...]
23andMe Launches New Genetic Report on Osteoporosis
31/01/2025
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME [...]
SAB BIO to Participate in Upcoming Investor Conferences
31/01/2025
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti- [...]
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
31/01/2025
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual [...]
OKYO Pharma Announces Chairman and CEO Acquire Shares
31/01/2025
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), [...]
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
31/01/2025
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]

Pages